Skip to main content
SpringerLink
Log in

Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 30 July 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Gisli Jenkins R, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, et al. Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

    Article  Google Scholar 

  2. George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019;7(3):271–82.

    Article  Google Scholar 

  3. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.

    Article  Google Scholar 

  4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, INPULSIS Trial Investigators, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

    Article  Google Scholar 

  5. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis [Internet]. Lancet Lancet Publishing Group; 2017 [cited 2020 Jul 14]; 389:1941–52. https://pubmed.ncbi.nlm.nih.gov/28365056/.

  6. Noth I, Anstrom KJ, Calvert SB, De Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. [Internet]; 2012 [cited 2020 Jul 14];186:88–95. https://pubmed.ncbi.nlm.nih.gov/22561965/.

  7. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. [Internet] W.B. Saunders Ltd; 2014 [cited 2020 Jul 14]; 108: 647–53. http://www.ncbi.nlm.nih.gov/pubmed/24529739.

  8. Tomassetti S. View of The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice [Internet]. [cited 2020 Jul 14]. https://mattioli1885journals.com/index.php/sarcoidosis/article/view/3023/2232.

  9. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47:1776–84.

    Article  CAS  Google Scholar 

  10. Margaritopoulos GA, Antoniou KM. Can warfarin be used in the treatment of pulmonary embolism in idiopathic pulmonary fibrosis? [Internet]. Am J Respir Crit Care Med. American Thoracic Society; 2016 [cited 2020 Jul 14]. pp 810–811. https://pubmed.ncbi.nlm.nih.gov/27035785/.

  11. Margaritopoulos GA, Antoniou KM. Reply: Heparin versus warfarin in interstitial pulmonary fibrosis: the quest for the right anticoagulant continues [Internet]. Am J Respir Crit Care Med. American Thoracic Society; 2017[cited 2020 Jul 14]. p. 142–3. https://pubmed.ncbi.nlm.nih.gov/28035862/.

  12. Crooks MG, Hart SP. Coagulation and anticoagulation in idiopathic pulmonary fibrosis [Internet]. Eur Respir Rev. European Respiratory Society; 2015 [cited 2020 Jul 14]; 24(137):392–9. https://pubmed.ncbi.nlm.nih.gov/26324800/.

  13. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, Du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. [Internet] Massachussetts Medical Society; 2011[cited 2020 Jul 17];365:1079–87. https://pubmed.ncbi.nlm.nih.gov/21992121/.

  14. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosiss. J Pharmacol Exp Ther. [Internet]. American Society for Pharmacology and Experimental Therapy; 2014 [cited 2020 Jul 17];349:209–20. https://pubmed.ncbi.nlm.nih.gov/24556663/.

  15. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, Du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet [Internet]; 2011[cited 2020 Jul 14];377:1760–69. https://pubmed.ncbi.nlm.nih.gov/21571362/.

  16. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJF. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One [Internet] Public Library of Science; 2016 [cited 2020 Jul 17]; 11:e0151425. https://pubmed.ncbi.nlm.nih.gov/27023440/.

  17. Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, Melgaard Nielsen K, Münster AMB, Myllärniemi M, Ravaglia C, Vanuytsel T, Wijsenbeek M. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events [Internet]. Respiration S. Karger AG; 2019 [cited 2020 Jul 17];97:173–184. https://pubmed.ncbi.nlm.nih.gov/30544129/.

  18. Kolonics-Farkas A, Šterclová M, Mogulkoc N, Kus J, Hájková M, Müller V, Jovanovic D, Tekavec-Trkanjec J, Littnerová S, Hejduk K, Vašáková M. anticoagulant use and bleeding risk in central european patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE. Drug Saf. 2020. https://doi.org/10.1007/s40264-020-00978-5.

    Article  PubMed  Google Scholar 

  19. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504. https://doi.org/10.1183/09031936.00077309.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark

    Elisabeth Bendstrup

  2. Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Alberta Health Services, Edmonton, AB, Canada

    Meena Kalluri

Authors
  1. Elisabeth Bendstrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meena Kalluri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth Bendstrup.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflicts of interest

Elisabeth Bendstrup has received unrestricted grants and fees outside this work from Boehringer Ingelheim and Hofmann La Roche. Meena Kalluri has no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Data sharing is not applicable to this article as no datasets were generated or analysed for this commentary.

Code availability

Not applicable.

Authors' contributions

Both authors contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bendstrup, E., Kalluri, M. Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics. Drug Saf 43, 953–955 (2020). https://doi.org/10.1007/s40264-020-00991-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-020-00991-8

Search

Navigation